Quick Answer
Prelude Therapeutics Inc reported Net Income Loss of -$99.50 million for the year ending 2025.
- Prelude Therapeutics Inc showed an increase of +21.8% in Net Income Loss from 2024 to 2025.
- This data is from Prelude Therapeutics Inc's annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$5.24 million | Q2 2019: -$5.56 million | Q3 2019: -$6.73 million | Q1 2020: -$9.51 million | Q2 2020: -$11.41 million | Q3 2020: -$16.76 million | Q1 2021: -$21.30 million | Q2 2021: -$26.87 million | Q3 2021: -$30.69 million | Q1 2022: -$29.47 million | Q2 2022: -$27.37 million | Q3 2022: -$29.96 million | Q1 2023: -$27.72 million | Q2 2023: -$30.43 million | Q3 2023: -$30.61 million | Q1 2024: -$31.43 million | Q2 2024: -$34.74 million | Q3 2024: -$32.27 million | Q1 2025: -$32.09 million | Q2 2025: -$31.23 million | Q3 2025: -$19.73 million.
- Over the full 7 years of available data (2019 to 2025), Prelude Therapeutics Inc's Net Income Loss has declined by 260.9%.
- Historical annual values: Fiscal year 2025: -$99.50 million | Fiscal year 2024: -$127.17 million | Fiscal year 2023: -$121.83 million | Fiscal year 2022: -$115.44 million | Fiscal year 2021: -$111.69 million | Fiscal year 2020: -$56.93 million | Fiscal year 2019: -$27.57 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: